
Sign up to save your podcasts
Or
Growing up in Austria as the daughter of two physicians, Lisa Anderson, co-founder and CEO of Paragonix Technologies, spent many evenings around the dinner table discussing patient care with her parents. After pursuing advanced studies in biomedical sciences and medical genetics, Anderson ventured back into patient care and launched a donor organ preservation and transport company to dramatically improve the standard of care for many donor recipients.
In this episode, Anderson speaks with host Geoff Pardo about the current issues in organ transport and how their first device—the Paragonix SherpaPak Cardiac Transport System—significantly decreases the number of adverse events less than 24 hours after heart transplant surgery. She also talks about the company’s transition to a service-based business with the development of the Paragonix app, their expansion into transporting lungs, livers, and kidneys, and the strategies used to develop a straightforward and high-performing device. She says, “We wanted to provide a simple device that provides superior clinical outcomes, is easy to us, and has an intuitive user profile when [organ recoveries] occur. We provide [surgical teams] with superior organ preservation.”
Links from this episode:
Gilde Healthcare
Paragonix Technologies
Paragonix SherpaPak Cardiac Transport System
4.8
5757 ratings
Growing up in Austria as the daughter of two physicians, Lisa Anderson, co-founder and CEO of Paragonix Technologies, spent many evenings around the dinner table discussing patient care with her parents. After pursuing advanced studies in biomedical sciences and medical genetics, Anderson ventured back into patient care and launched a donor organ preservation and transport company to dramatically improve the standard of care for many donor recipients.
In this episode, Anderson speaks with host Geoff Pardo about the current issues in organ transport and how their first device—the Paragonix SherpaPak Cardiac Transport System—significantly decreases the number of adverse events less than 24 hours after heart transplant surgery. She also talks about the company’s transition to a service-based business with the development of the Paragonix app, their expansion into transporting lungs, livers, and kidneys, and the strategies used to develop a straightforward and high-performing device. She says, “We wanted to provide a simple device that provides superior clinical outcomes, is easy to us, and has an intuitive user profile when [organ recoveries] occur. We provide [surgical teams] with superior organ preservation.”
Links from this episode:
Gilde Healthcare
Paragonix Technologies
Paragonix SherpaPak Cardiac Transport System
38,465 Listeners
43,944 Listeners
32,031 Listeners
46 Listeners
92 Listeners
81,761 Listeners
30,293 Listeners
112,814 Listeners
787 Listeners
8,385 Listeners
14,859 Listeners
178 Listeners